How should low female libido be evaluated and managed, including assessment of reversible factors and appropriate pharmacologic therapies?

Management of Low Female Libido

For low female libido (hypoactive sexual desire disorder), begin by screening with the Decreased Sexual Desire Screener, assess and modify reversible biopsychosocial factors, then initiate mindfulness-based cognitive behavioral therapy as first-line treatment, with pharmacologic options reserved for persistent cases: flibanserin or bremelanotide for premenopausal women, and transdermal testosterone (300 µg/d) for postmenopausal women. 1, 2, 3

Initial Assessment and Diagnosis

Start by directly asking about sexual concerns during routine visits, as patients rarely initiate these discussions 1. The diagnosis requires:

• Persistent absence of sexual thoughts/fantasies and lack of desire for sexual activity for ≥6 months
• Associated marked personal distress or interpersonal difficulties
• Not better explained by another disorder, medication, or medical condition 2, 3

Use the Decreased Sexual Desire Screener as a validated tool to identify HSDD and determine need for further evaluation 3.

Evaluation of Reversible Factors

Assess the following modifiable contributors systematically 1:

Biological factors:

• Medications that increase serotonin, prolactin, or opioids (decrease libido)
• Medications that decrease dopamine, melanocortin, oxytocin, or norepinephrine (decrease libido)
• Medical conditions (depression, chronic illness, pain disorders)
• Hormonal status and menopausal state

Psychological factors:

• Depression and anxiety
• History of trauma or abuse
• Body image concerns
• Performance anxiety

Interpersonal factors:

• Relationship quality and conflict
• Partner sexual dysfunction
• Communication patterns

Sociocultural factors:

• Cultural or religious beliefs about sexuality
• Life stressors and role demands

Treatment Algorithm

First-Line: Psychological Interventions

Mindfulness-based cognitive behavioral therapy has the strongest evidence for improving low sexual desire 4. This should be initiated alongside:

• Psychoeducation about normal sexual response
• Behavioral therapy techniques
• Cognitive restructuring of negative thoughts about sex 1, 2

Second-Line: Pharmacologic Treatment

For Premenopausal Women:

Two FDA-approved options exist 3, 5:

1. Flibanserin (first FDA-approved medication for HSDD)

   • Modest benefit above placebo
   • Significant proportion experience side effects
   • Currently the only FDA-approved option for premenopausal generalized acquired HSDD 2

2. Bremelanotide (melanocortin receptor agonist)

   • Recently FDA-approved for acquired, generalized HSDD
   • Alternative mechanism of action 3, 5

Off-label considerations (limited evidence):

• Bupropion or buspirone may be considered despite limited safety/efficacy data 2

For Postmenopausal Women:

Transdermal testosterone patch (TTP) 300 µg/d is the best-studied and most effective androgen therapy 6:

• Increases satisfying sexual events by approximately 1-2 additional events per month compared to placebo
• Improves all domains: arousal, pleasure, orgasm, self-image, responsiveness
• Reduces personal distress by 65-68% (vs 40-48% with placebo)
• Increases orgasms by >115% (vs 38% with placebo)
• Effective in both surgically and naturally menopausal women
• Effective whether or not concurrent estrogen therapy is used 6

Critical dosing note: The 300 µg/d dose showed efficacy, while 150 µg/d and 450 µg/d doses did NOT show benefit 6. This is off-label use but supported by multiple large RCTs 6, 2.

Important Caveats

Androgen therapy should only be used when clinical AND biochemical parameters indicate androgen deficiency 7. However, the 2014 Endocrine Society guideline notes that age and surgical menopause (bilateral salpingo-oophorectomy) are key risk factors, with HSDD more frequent in women <45 years old with past BSO 6.

Common pitfall: Two large phase III trials of transdermal testosterone gel (0.22 g/d) showed NO benefit over placebo 6, highlighting that formulation and dosing matter significantly—only the 300 µg/d patch formulation has proven efficacy.

Contraindication awareness: Screen for contraindications to hormonal therapy and ensure informed consent about off-label use of testosterone in postmenopausal women 6.

Monitoring

Track treatment progress using validated measures of sexual function, including:

• Frequency of satisfying sexual events
• Level of sexual desire
• Personal distress levels
• All domains of sexual function (arousal, pleasure, orgasm) 1

Adjust therapy based on response, tolerability, and patient preferences, recognizing that combination approaches (psychological + pharmacologic) may be needed for optimal outcomes 1, 4.